The New York Times (2/3, A1, Forsythe, Bogdanich) reports, “McKinsey & Company, the consultant to blue-chip corporations and governments around the world, has agreed to pay $573 million to settle investigations into its role in helping ‘turbocharge’ opioid sales, a rare instance of it being held publicly accountable for its work with clients.” The firm “has reached the agreement with attorneys general in 47 states, the District of Columbia and five territories, according to five people familiar with the negotiations.” The settlement “comes after lawsuits unearthed a trove of documents showing how McKinsey worked to drive sales of Purdue Pharma’s OxyContin” pain medication “amid an opioid epidemic in the United States that has contributed to the deaths of more than 450,000 people over the past two decades.”
Related Links:
— “McKinsey Settles for Nearly $600 Million Over Role in Opioid Crisis ” Michael Forsythe and Walt Bogdanich, The New York Times, February 3, 2021